Abera Bioscience develops next-generation nasal vaccines using a modular OMV platform that enables rapid design, cost-effective production and strong mucosal and systemic immunity.
Abera Bioscience publishes a video recording of the presentation given by CEO Maria Alriksson at Aktiespararna’s Life Science Event Thursday, November 12, 2026. The presentation
Abera Bioscience AB (“Abera” or the “Company”) today announces that the Dutch regulatory authority, the Central Committee on Research Involving Human Subjects (CCMO), has approved
Abera Bioscience AB (“Abera” or the “Company”) today announces that a scientific article on the Company’s intranasal pneumococcal vaccine has been published in the journal
Abera Bioscience’s OMV platform enables rapid, modular vaccine design with high flexibility across disease targets. The technology supports efficient, scalable manufacturing and induces both mucosal and systemic immunity, making it suitable for seasonal, bacterial and emerging pathogens.
The pipeline includes a serotype-independent nasal pneumococcal vaccine preparing for Phase 1 and a nasal influenza vaccine progressing through preclinical development. The platform’s adaptability also provides opportunities for future programs within pandemic preparedness and additional infectious disease areas.
Abera’s platform is designed with global health in mind. Our OMV technology enables scalable, cost-effective vaccine production without eggs, using controlled liquid fermentation. Vaccines can be delivered as a simple nasal spray and have potential for powder formulation — reducing the need for needles, cold chain and complex logistics.
This makes our vaccines well suited for both high-income countries and low-resource settings.
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
